|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TGDS |
Gene summary for TGDS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TGDS | Gene ID | 23483 |
| Gene name | TDP-glucose 4,6-dehydratase | |
| Gene Alias | CATMANS | |
| Cytomap | 13q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O95455 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23483 | TGDS | LZE4T | Human | Esophagus | ESCC | 1.29e-06 | 1.32e-01 | 0.0811 |
| 23483 | TGDS | LZE22T | Human | Esophagus | ESCC | 2.07e-03 | 2.11e-01 | 0.068 |
| 23483 | TGDS | LZE24T | Human | Esophagus | ESCC | 8.81e-05 | 1.44e-01 | 0.0596 |
| 23483 | TGDS | P2T-E | Human | Esophagus | ESCC | 1.78e-11 | 2.07e-01 | 0.1177 |
| 23483 | TGDS | P4T-E | Human | Esophagus | ESCC | 6.33e-14 | 3.40e-01 | 0.1323 |
| 23483 | TGDS | P5T-E | Human | Esophagus | ESCC | 1.35e-03 | 7.65e-02 | 0.1327 |
| 23483 | TGDS | P8T-E | Human | Esophagus | ESCC | 3.92e-17 | 2.35e-01 | 0.0889 |
| 23483 | TGDS | P9T-E | Human | Esophagus | ESCC | 5.69e-04 | 1.15e-01 | 0.1131 |
| 23483 | TGDS | P10T-E | Human | Esophagus | ESCC | 2.37e-15 | 2.83e-01 | 0.116 |
| 23483 | TGDS | P11T-E | Human | Esophagus | ESCC | 1.70e-07 | 3.87e-01 | 0.1426 |
| 23483 | TGDS | P12T-E | Human | Esophagus | ESCC | 4.02e-26 | 4.13e-01 | 0.1122 |
| 23483 | TGDS | P15T-E | Human | Esophagus | ESCC | 1.02e-11 | 2.12e-01 | 0.1149 |
| 23483 | TGDS | P16T-E | Human | Esophagus | ESCC | 8.60e-18 | 2.71e-01 | 0.1153 |
| 23483 | TGDS | P17T-E | Human | Esophagus | ESCC | 1.92e-03 | 1.66e-01 | 0.1278 |
| 23483 | TGDS | P20T-E | Human | Esophagus | ESCC | 3.04e-09 | 1.50e-01 | 0.1124 |
| 23483 | TGDS | P21T-E | Human | Esophagus | ESCC | 3.45e-10 | 1.23e-01 | 0.1617 |
| 23483 | TGDS | P22T-E | Human | Esophagus | ESCC | 1.91e-04 | 4.47e-02 | 0.1236 |
| 23483 | TGDS | P23T-E | Human | Esophagus | ESCC | 8.01e-06 | 1.95e-01 | 0.108 |
| 23483 | TGDS | P24T-E | Human | Esophagus | ESCC | 4.87e-15 | 1.12e-01 | 0.1287 |
| 23483 | TGDS | P26T-E | Human | Esophagus | ESCC | 3.84e-17 | 2.26e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00024431 | Cervix | HSIL_HPV | leukocyte mediated immunity | 41/737 | 440/18723 | 3.14e-07 | 1.76e-05 | 41 |
| GO:00022631 | Cervix | HSIL_HPV | cell activation involved in immune response | 28/737 | 279/18723 | 5.84e-06 | 2.13e-04 | 28 |
| GO:000227411 | Cervix | HSIL_HPV | myeloid leukocyte activation | 23/737 | 223/18723 | 2.53e-05 | 7.53e-04 | 23 |
| GO:0002366 | Cervix | HSIL_HPV | leukocyte activation involved in immune response | 26/737 | 275/18723 | 3.52e-05 | 9.72e-04 | 26 |
| GO:004645611 | Cervix | HSIL_HPV | icosanoid biosynthetic process | 10/737 | 56/18723 | 5.80e-05 | 1.40e-03 | 10 |
| GO:000151611 | Cervix | HSIL_HPV | prostaglandin biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
| GO:004645711 | Cervix | HSIL_HPV | prostanoid biosynthetic process | 7/737 | 31/18723 | 1.64e-04 | 3.14e-03 | 7 |
| GO:00066927 | Cervix | HSIL_HPV | prostanoid metabolic process | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
| GO:00066937 | Cervix | HSIL_HPV | prostaglandin metabolic process | 8/737 | 49/18723 | 5.99e-04 | 8.37e-03 | 8 |
| GO:00066907 | Cervix | HSIL_HPV | icosanoid metabolic process | 12/737 | 123/18723 | 3.36e-03 | 3.04e-02 | 12 |
| GO:00066362 | Cervix | HSIL_HPV | unsaturated fatty acid biosynthetic process | 7/737 | 51/18723 | 3.65e-03 | 3.25e-02 | 7 |
| GO:00024432 | Cervix | N_HPV | leukocyte mediated immunity | 39/534 | 440/18723 | 3.94e-10 | 2.24e-07 | 39 |
| GO:000227421 | Cervix | N_HPV | myeloid leukocyte activation | 21/534 | 223/18723 | 1.78e-06 | 9.21e-05 | 21 |
| GO:00022632 | Cervix | N_HPV | cell activation involved in immune response | 20/534 | 279/18723 | 1.59e-04 | 2.82e-03 | 20 |
| GO:00023661 | Cervix | N_HPV | leukocyte activation involved in immune response | 19/534 | 275/18723 | 3.66e-04 | 5.35e-03 | 19 |
| GO:004645621 | Cervix | N_HPV | icosanoid biosynthetic process | 7/534 | 56/18723 | 1.02e-03 | 1.20e-02 | 7 |
| GO:0043299 | Cervix | N_HPV | leukocyte degranulation | 7/534 | 73/18723 | 4.74e-03 | 3.51e-02 | 7 |
| GO:0002444 | Cervix | N_HPV | myeloid leukocyte mediated immunity | 8/534 | 99/18723 | 7.37e-03 | 4.80e-02 | 8 |
| GO:00485119 | Endometrium | AEH | rhythmic process | 67/2100 | 298/18723 | 1.69e-08 | 1.04e-06 | 67 |
| GO:00516568 | Endometrium | AEH | establishment of organelle localization | 77/2100 | 390/18723 | 4.89e-07 | 1.94e-05 | 77 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012505 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
| hsa0125012 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
| hsa012504 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
| hsa0125011 | Oral cavity | OSCC | Biosynthesis of nucleotide sugars | 25/3704 | 37/8465 | 2.93e-03 | 7.49e-03 | 3.81e-03 | 25 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TGDS | SNV | Missense_Mutation | c.610G>A | p.Glu204Lys | p.E204K | O95455 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| TGDS | SNV | Missense_Mutation | novel | c.17N>T | p.Trp6Leu | p.W6L | O95455 | protein_coding | tolerated_low_confidence(0.43) | benign(0) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TGDS | SNV | Missense_Mutation | c.751N>T | p.Pro251Ser | p.P251S | O95455 | protein_coding | tolerated(0.07) | benign(0.089) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TGDS | SNV | Missense_Mutation | c.270G>T | p.Glu90Asp | p.E90D | O95455 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TGDS | SNV | Missense_Mutation | c.653G>T | p.Arg218Met | p.R218M | O95455 | protein_coding | deleterious(0.04) | possibly_damaging(0.77) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TGDS | SNV | Missense_Mutation | novel | c.148N>T | p.Asp50Tyr | p.D50Y | O95455 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TGDS | SNV | Missense_Mutation | c.853A>G | p.Met285Val | p.M285V | O95455 | protein_coding | tolerated(0.74) | benign(0) | TCGA-AX-A06L-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TGDS | SNV | Missense_Mutation | novel | c.80G>A | p.Gly27Asp | p.G27D | O95455 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TGDS | SNV | Missense_Mutation | rs748710870 | c.578N>A | p.Ser193Asn | p.S193N | O95455 | protein_coding | deleterious(0) | possibly_damaging(0.545) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TGDS | SNV | Missense_Mutation | c.215N>G | p.Phe72Cys | p.F72C | O95455 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |